Ethyl (3R,4R,5S)-5-acetamido-4-(diallylamino)-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate

Catalog No. :
ACJGTD145
CAS No. :
2254819-34-4
Molecular Formula :
C22H36N2O4
Molecular Weight :
392.54

IUPAC Name:ethyl (3R,4R,5S)-5-acetamido-4-(diallylamino)-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate

Ethyl (3R,4R,5S)-5-acetamido-4-(diallylamino)-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameEthyl (3R,4R,5S)-5-acetamido-4-(diallylamino)-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate
IUPAC Nameethyl (3R,4R,5S)-5-acetamido-4-(diallylamino)-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate
Molecular FormulaC22H36N2O4
Molecular Weight392.54
SMILESCCC(O[C@@H]1C=C(C(OCC)=O)C[C@H](NC(C)=O)[C@H]1N(CC=C)CC=C)CC
InChI KeyWKPPBEHSYVUAHF-PWRODBHTSA-N
SynonymOseltamivir Impurity 15;(3S,4R,5R)-ethyl 4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-enecarboxylate;1-Cyclohexene-1-carboxylic acid, 5-(acetylamino)-4-(di-2-propen-1-ylamino)-3-(1-ethylpropoxy)-, ethyl ester, (3R,4R,5S)-;(3R,4R,5S)-Ethyl 5-acetamido-4-(diallylamino)-3-(pentan-3-yloxy)cyclohex-1-enecarboxylate (Oseltamivir Impurity)
CAS No.2254819-34-4

Synthetic Route by SureRoute

1. ACJGTD145 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACJGTD145 route product structure diagram
    ACJGTD1452254819-34-4
Inquiry

2. ACJGTD145 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACJGTD145 route product structure diagram
    ACJGTD1452254819-34-4
Inquiry

Comments (0)